宝藿苷I

分析标准品,HPLC≥98%

Baohuoside I

CAS号：113558-15-9

分子式：C27H30O10

分子量：514.52

MDL：MFCD15071140

别名：淫羊藿次苷II; 宝藿苷 I; 宝藿苷Ⅰ; 淫羊藿次苷II

产品介绍

熔点：202-203℃

沸点：759.4℃ at 760mmHg

比旋光度：(c, 0.09 in MeOH)-121

外观：黄色针状结晶

溶解性：DMSO  :  ≥  32  mg/mL (62.19  mM)

储存条件：2-8℃

注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

参考文献(42篇)

42. [IF=2.5] Zheng Junzuo et al."Pharmacokinetics of seven major components in Aβ1-42-treated rats after oral administration of an aqueous extract of Curculiginis Rhizoma and Epimedii Folium."Journal of Natural Medicines.2024 Nov;:1-16

41. [IF=3.8] Jialu Shen et al."Insights into inhibitory mechanisms: Unraveling the structure-activity relationship of dietary flavonoids on gut bacterial β-glucuronidase."Journal of Functional Foods.2024 Nov;122:106510

40. [IF=2.1] Jun-Tao Sun et al."Exploring the protective effect and mechanism of icariside II on the bladder in a rat model of radiation cystitis based on transcriptome sequencing."INTERNATIONAL JOURNAL OF RADIATION BIOLOGY.

39. [IF=4.4] Chen Yangfeng et al."In Vitro evaluation of the anti-pancreatic cancer activity of epimedium herb."Frontiers in Pharmacology.2024 Jul;15:

38. [IF=6.1] Xiuchun Li et al."Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps."LIFE SCIENCES".2024 Jun;346:122648

37. [IF=6] Dong Xie et al."Pharmacodynamic material basis and mechanism of Tenghuang Jiangu Wan on osteoarthritis using UPLC-Q-TOF-MS integrated with target network pharmacology."Arabian Journal of Chemistry".2024 Apr;17:105711

36. [IF=1.6] Liu Huimin et al."Identification and Characterization of the Chemical Constituents of Qianlie Shule Capsules by UPLC-Q-Orbitrap-MS/MS."JOURNAL OF AOAC INTERNATIONAL".2024 Feb;:

35. [IF=8.4] Ting An et al."De novo biosynthesis of anticarcinogenic icariin in engineered yeast."METABOLIC ENGINEERING.2023 Nov;80:207

34. [IF=5.4] Yi-min Liu et al."Uncovering the key pharmacodynamic material basis and possible molecular mechanism of extract of Epimedium against liver cancer through a comprehensive investigation."JOURNAL OF ETHNOPHARMACOLOGY.2023 Dec;317:116765

33. [IF=5.572] Zhen Zhao et al."An integrated strategy combining network toxicology and feature-based molecular networking for exploring hepatotoxic constituents and mechanism of Epimedii Folium-induced hepatotoxicity in vitro."FOOD AND CHEMICAL TOXICOLOGY.2023 Jun;176:

32. [IF=6.208] Jiaqi Zhang et al."The Effect of Epimedium Isopentenyl Flavonoids on the Broiler Gut Health Using Microbiomic and Metabolomic Analyses."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2023 Jan;24(8):7646

31. [IF=6.832] Li  Zhang et al."Erxian herbal pair enhances bone formation in infected bone nonunion models and attenuates lipopolysaccharide-induced osteoblastinhibition by regulating miRNA-34a-5p."Bioengineered.2022;13(6):14339-14356

30. [IF=6.208] Yu Yao et al."A Novel 3-O-rhamnoside: 2″-O-xylosyltransferase Responsible for Terminal Modification of Prenylflavonol Glycosides in Epimedium pubescens Maxim.."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(24):16050

29. [IF=5.895] Fang Liu et al."Co-Immobilizing Two Glycosidases Based on Cross-Linked Enzyme Aggregates to Enhance Enzymatic Properties for Achieving High Titer Icaritin Biosynthesis."JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2022;XXXX(XXX):XXX-XXX

28. [IF=5.988] Li  Pin et al."Epimedium koreanum Nakai–Induced Liver Injury—A Mechanistic Study Using Untargeted Metabolomics."Frontiers in Pharmacology.2022 Jul;0:2288

27. [IF=1.902] Ting Zhang et al."The influence of essential oils from ZhaLi NuSi Prescription on the pharmacokinetics of its non-volatile components in normal rats."Biomedical Chromatography. 2021 Oct 21

26. [IF=2.886] Yangyang Guo et al."Baohuoside I via mTOR Apoptotic Signaling to Inhibit Glioma Cell Growth."Cancer Manag Res. 2020; 12: 11435–11444

25. [IF=2.886] Fubiao Ni et al."Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling."Cancer Manag Res. 2019; 11: 10609–10621

24. [IF=3.645] Hongmin Zhang et al."Simultaneous determination of five isoflavones in rat plasma by LC-MS/MS: Comparative pharmacokinetic characteristics of Puerariae lobatae radix in normal and type 2 diabetic rats."J Sep Sci. 2019 Aug;42(16):2592-2601

23. [IF=3.757] Congyan Liu et al."Enhanced hydrolysis and antitumor efficacy of Epimedium flavonoids mediated by immobilized snailase on silica."Process Biochem. 2019 Nov;86:80

22. [IF=4.36] Kun Shi et al."Epimedii Folium and Curculiginis Rhizoma ameliorate lipopolysaccharides-induced cognitive impairment by regulating the TREM2 signaling pathway."J Ethnopharmacol. 2022 Feb;284:114766

21. [IF=4.411] Zhenxian Qin et al."A Widely Metabolomic Analysis Revealed Metabolic Alterations of Epimedium Pubescens Leaves at Different Growth Stages."Molecules. 2020 Jan;25(1):137

20. [IF=3.263] Jing Yang et al."Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells."Eur J Pharmacol. 2019 Mar;846:12

19. [IF=6.529] Congyan Liu et al."Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats."Biomed Pharmacother. 2017 Oct;94:1048

18.  Liu, Congyan, et al. "Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats." Biomedicine & Pharmacotherapy 94 (2017): 1048-1056.https:##doi.org/10.1016/j.biopha.2017.07.163

17.  Yang, Jing, et al. "Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells." European journal of pharmacology 846 (2019): 12-22.https:##doi.org/10.1016/j.ejphar.2018.12.026

16.  许婷,黄萌萌,李瑞云,杨茹,刘丽芳,陈彦.多基原淫羊藿不同部位质量评价研究[J].中草药,2020,51(01):190-196.

15.  刘聪燕,李瑞云,马程遥,刘玉萍,瞿鼎,李晓琦,陈彦.壳聚糖交联介孔二氧化硅固定化β-葡萄糖苷酶生物转化淫羊藿苷研究[J].中草药,2021,52(03):685-691.

14.  彭静, 马益华, 陈彦,等. 固定化蜗牛酶同时生物转化淫羊藿中4种黄酮苷[J]. 中成药, 2016, 38(9):1984-1990.

13.  高霞, 陈彦, 王莹,等. 糊精湿法制粒对淫羊藿总黄酮酶解的影响[J]. 中成药, 2014, 36(007):1392-1397.

12.  高霞, 刘璇, 陈彦,等. 淫羊藿总黄酮的生物转化过程分析[J]. 中国中药杂志, 2013, 38(23):4079.

11.  刘聪燕, 高霞, 陈彦,等. 淫羊藿总黄酮在骨质疏松大鼠体内的药动学行为[J]. 中成药, 2017, 39(008):1595-1600.

10.  刘聪燕, 高霞, 黄萌萌,等. 淫羊藿总黄酮仿生酶解肠溶胶囊的制备及评价[J]. 中草药, 2016(20).

9.  张燕. 大孔吸附树脂分离纯化淫羊藿EF5黄酮[J]. 北方药学, 2015, 000(011):11-13.

8.  刘聪燕  高霞  陈彦 等. 仿生酶解肠溶胶囊提高淫羊藿总黄酮口服生物利用度的可行性研究[J]. 中国医药工业杂志  2016(9期):1158-1164.

7.  王莹  高霞  陈彦 等. 卡波姆对淫羊藿总黄酮酶解效果的影响[J]. 中国实验方剂学杂志  2014  20(009):1-5.

6.  杨茹  刘聪燕  许婷 等. 5种大孔吸附树脂对淫羊藿总黄酮的吸附特性考察[J]. 中国实验方剂学杂志  2020  v.26(06):121-128.

5.  顾慧敏, 孙娥, 李杰,等. 炮制辅料羊脂油对宝藿苷Ⅰ-胆酸盐自组装胶束形成与吸收的影响[J]. 中国中药杂志, 2019, v.44(23):133-140.

4.  刘玉萍, 丁学芳, 黄萌萌,等. 淫羊藿苷在不同骨质疏松大鼠模型中肠道吸收代谢研究[J]. 中国中药杂志, 2016(13):2532-2537.

3.  高霞, 陈彦, 王莹,等. 淫羊藿苷仿生酶解过程的多因素考察[J]. 药学学报, 2013(11):1716-1721.

2.  李瑞云  刘聪燕  许婷 等. 交联纳米SiO_2固定化蜗牛酶的制备表征及转化淫羊藿苷研究[J]. 中草药  2019  v.50;No.655(20):57-63.

1.  杨轶舜  张彤  丁越 等. 3种淫羊藿苷次生产物的制备及HPLC测定[J]. 中成药  2020  042(003):779-782.

从2011年开始我们致力于在生命科学领域、生物医学实验技术及论文润色服务，协助客户各类实验服务及论文润色十余年，是客户您值得信赖的科研合作伙伴!

如果您受时间、试验条件等限制而无法完成您的课题研究，欢迎您与我们联系。

实验技术服务：